Why Bitcoin’s Record High May Be Followed by a Decline Below $120,000
Bitcoin’s record-setting rally shows signs of fatigue as holders reduce accumulation and long-term investors take profits. Unless demand revives, BTC could fall below $120,000 before attempting another rebound.
Leading digital asset Bitcoin (BTC) hit a record high of $126,199 on Monday, marking a major milestone. However, since reaching this peak, the coin has largely traded sideways, showing signs of hesitation among traders.
With many market participants anticipating a potential move below the $120,000 region, on-chain indicators suggest that a short-term downward trend could be looming.
Bitcoin Momentum Weakens as Holders Exit
Subtle signs of weakening momentum accompany BTC’s recent sideways trend. According to Glassnode, the coin’s Holder Accumulation Ratio has trended downward since Monday and continues to decline.
At press time, the ratio is at 54.42%, falling by 2% in the past four days.
For token TA and market updates: Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter
BTC Holder Accumulation Ratio. Source:
Glassnode
The Holder Accumulation Ratio measures the proportion of active holders increasing their positions versus those decreasing them.
A higher ratio indicates that more BTC is being retained, signaling strong confidence and accumulation among investors.
Conversely, when it falls, as seen over the past few days, it suggests that more holders are selling or moving their coins rather than accumulating them.
At the same time, BTC’s Liveliness has resumed its uptrend since Monday. The metric closed October 8 at 0.6298.
BTC Liveliness. Source:
Glassnode
Liveliness tracks the movement of long-held/dormant tokens. It does this by measuring the ratio of an asset’s coin days destroyed to the total coin days accumulated.
When the metric falls, LTHs are moving their assets off exchanges, a move seen as a bullish signal of accumulation.
Conversely, when it climbs like this, it means that LTHs are moving their coins and selling them. This signals caution and a buildup of a profit-taking trend that could lower BTC’s price.
Can Buyers Step In Before a Deeper Drop?
Without renewed buying interest, BTC risks slipping toward the $120,000 zone. A breach of the support floor at $120,090 could trigger a further decline to $118,922.
BTC Price Analysis. Source:
TradingView
However, if new buyers enter the market and demand picks up, the cryptocurrency could stabilize above current levels and potentially revisit its all-time high of $126,199.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
